Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | LIPA | P38571 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981105 | 0.82 | EPHX1 (0.33) | EPHX1LIPAHSD11B1 | |
| SCHEMBL3983375 | 0.75 | HSD11B1 (0.43) | TSHRHSD11B1 | |
| SCHEMBL12231001 | 0.75 | POLB (0.48) | POLBTDP1SLC1A2SLC1A1KDM4E | |
| SCHEMBL34468414 | 0.72 | POLB (0.37) | EPHX1POLBTDP1SLC1A2SLC1A1 | |
| SCHEMBL3984067 | 0.72 | POLB (0.37) | EPHX1POLBTDP1SLC1A2SLC1A1 | |
| SCHEMBL23645187 | 0.72 | GRM2 (0.41) | EPHX1SLC1A2SLC1A1GLALIPA | |
| SCHEMBL1073419 | 0.72 | GLA (0.43) | EPHX1GLALIPALMNAPMP22 | |
| SCHEMBL3984150 | 0.72 | MAPT (0.33) | EPHX1GLALIPAKDM4EHTT | |
| SCHEMBL14653071 | 0.72 | POLB (0.39) | POLBTDP1SLC1A2SLC1A1KDM4E | |
| SCHEMBL24425352 | 0.72 | POLB (0.39) | POLBTDP1SLC1A2SLC1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562575-B1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LAB (US) | 2009-05-20 | — | — | EP | claimed |
| EP-1562575-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | Abbott Laboratories (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | claimed |
| WO-2004037241-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| EP-1562575-B1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LAB (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1562575-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | Abbott Laboratories (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | disclosed |
| WO-2004037241-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | EPHX1 1196/4885POLB 2882/4885TDP1 1863/4885 |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | EPHX1 1196/4885POLB 2882/4885TDP1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.